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Structure-function relationships in antimicrobial peptides have been extensively investigated in order to
obtain improved analogs. Most of these studies have targeted either -helical peptides or -sheet peptides with
multiple disulfide bridges. Tigerinins are short, nonhelical antimicrobial peptides with a single disulfide
bridge. In this study, we have synthesized several analogs of tigerinin 1 with an aim to understand the
structural basis of activity as well as improve its activity. The studies demonstrate that the loop structure of
tigerinin 1 is essential for its optimal activity. However, linearization with increased cationic charges can
compensate for loss of loop structure to some extent. Morphology of the cells after treatment with the active
analogs shows extensive leakage of cytoplasmic contents. Tigerinin 1 and two of its analogs exhibit impressive
activity against a variety of clinical bacterial isolates.
Antimicrobial peptides with broad-spectrum activity are
widely distributed in nature and have been characterized from
plants, insects, and amphibians as well as mammals, including
humans (1, 3, 6–8, 21, 26, 31). Recent studies have confirmed
their primacy in the innate immune system of organisms across
the evolutionary scale (6, 12, 14). Although a majority of these
peptides are believed to function by permeabilizing mem-
branes, mechanisms involving inhibition of DNA, RNA, and/or
protein biosynthesis have also been proposed (15, 22, 26, 33,
39). These peptides kill microorganisms rapidly compared to
other antibiotics, and this class of peptides appears to be re-
fractory to the development of resistance (13). All these at-
tributes make them attractive candidates as next-generation
therapeutic agents for treating multidrug-resistant bacterial
infections. Structure-function studies on antimicrobial pep-
tides have added significance in this direction, as there is a
rapid increase in the emergence of microbes resistant to con-
ventionally used antibiotics in recent years (10, 20, 36). How-
ever, a majority of such studies have been confined to linear
peptides with a propensity for amphiphilic -helical structure
or amphiphilic -sheet peptides stabilized by multiple disulfide
bridges (9, 17, 18, 24, 30, 31, 35). In contrast to this, only a few
nonhelical antimicrobial peptides with a single disulfide bridge,
like thanatin and bactenecin, have been used in structure-
function studies (11, 25, 37, 38). We have recently character-
ized a novel family of short, nonhelical antimicrobial peptides
called tigerinins from the skin secretions of the Indian frog
Rana tigerina (27). Tigerinins are a unique family of 11- to
12-residue peptides and are characterized by the presence of a
stretch of predominantly hydrophobic amino acids with one
cationic residue and an amidated C terminus. They also con-
tain two cysteine residues linked by a disulfide bond to form a
loop of nine amino acid residues. Tigerinins are thus distinctly
different from any other known antimicrobial peptides, includ-
ing the “rana box”-containing brevinin group of peptides from
the genus Rana (16, 23, 29), and could provide novel lead
molecules for design of antimicrobial peptides with possible
therapeutic applications. In this study, we have chosen the
most-active member of this family, tigerinin 1 (TGN-1), for
structure-function analysis.
The sequences of the peptides used in the study are shown
in Table 1. The synthesis and characterization of TGN-1 has
been described earlier (27). Other peptides described in this
study were synthesized manually on amide crowns (Chiron
Technologies) by the solid-phase method using fluorenylme-
thoxy carbonyl chemistry (2). All amino acids were added as
fluorenylmethoxy carbonyl hydroxy benzotriazole active esters.
The peptides were cleaved from the resin by treatment with
trifluoroacetic acid-thioanisole-phenol-water-ethanedithiol
(16.5:1:1:1:0.5, vol/vol) overnight at room temperature. The
peptides were checked for purity by high-performance liquid
chromatography using a reverse-phase column (Water’s
Bondapak C18) using a solvent system of 0.1% aqueous trif-
luoroacetic acid and acetonitrile. The cysteines were depro-
tected with mercury(II) acetate in the ratio of 2 equivalents for
each equivalent of cysteine. Mercuric sulfide salts formed were
precipitated with 20 equivalents of -mercaptoethanol. The
peptides were then desalted and the disulfide bridges were
formed by oxidation in 20% dimethyl sulfoxide (34). The dis-
ulfide-bridged peptides were checked for purity by high-per-
formance liquid chromatography. The peptides were further
characterized by matrix-assisted laser desorption ionization
mass spectrometry.
Lethal concentrations (LCs) of the peptides were deter-
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mined by growing the microorganism in nutrient broth (Bacto
Difco nutrient broth) to mid-logarithmic phase and diluting to
106 CFU/ml in 10 mM sodium phosphate buffer (pH 7.4) (17,
32). Aliquots of 100 l of culture so diluted were incubated
with different concentrations of the peptides (20 to 200 g/ml
in multiples of 20 g/ml) for 2 h at 37°C, at the end of which
suitably diluted aliquots were plated on nutrient agar plates.
The plates were incubated for 18 h at 37°C, and colonies
formed were counted. Strains which were more sensitive were
evaluated for growth at lower concentrations in multiples of
either 2 or 5 g/ml. The concentration of the peptides at which
no viable colonies were formed was taken as the LC. The
average of two independent experiments done in duplicate was
taken for the calculation of LCs. The kinetics of killing was
evaluated for Escherichia coli and Staphylococcus aureus by
determining the viable cell counts as a function of time.
Samples were processed for electron microscopy in the fol-
lowing way. Liquid cultures of E. coli cells grown up to mid-
logarithmic phase were washed well in sodium phosphate
buffer (10 mM) and centrifuged for 3 min at 1,500  g. The
pellet formed was fixed in 2.5% glutaraldehyde in 0.1 M phos-
phate buffer for 3 h at 4°C. After fixation the pellet was washed
with 0.1 M phosphate buffer three times. The samples were
then postfixed on 1% osmium tetroxide in 0.1 M phosphate
buffer for 2 h. Fixed samples were then thoroughly washed with
phosphate buffer, following which they were dehydrated
through a series of acetone gradients. Dehydrated samples
were passed through propylene oxide and infiltrated with ep-
oxy resin overnight. Samples were then embedded in pure resin
(epoxy resin) and cured at 60°C for 72 h. Golden color sections
were obtained using a Reichert Ultracut E microtome and
were stained with 2% uranyl acetate and Reynold’s lead ci-
trate, and the sections were observed under a JEOL 100 CX
electron microscope at 80 kV. Test samples were prepared by
treating the E. coli cells with the peptides at their LCs (108 cells
in 100 l were treated with 70 g of the peptides) for different
lengths of time (5 to 30 min) and then fixed with glutaralde-
hyde and processed the same way as described above.
Initial evaluations of the antibacterial activities of the pep-
tides were done on E. coli W 160-37 and S. aureus ATCC 8530
strains, and the results are shown in Table 1. TGN-1 was active
against both these strains, with LCs in the range of 8 to 12
g/ml. TGN-1 is amidated at the C terminus, and TGN-1 OH
is its analog with a C-terminal free COOH group. This analog
was almost inactive, with LCs of 200 g/ml against both mi-
croorganisms, and this indicates that amidation at the C ter-
minus is essential for its activity. The importance of positive
charges on the peptide in its initial interaction with the nega-
tively charged outer bacterial surface, which has a bearing on
its antimicrobial activity, is well established (6, 31). Thus, the
low activity of the analog with free C-terminal acid which
would make it less cationic than TGN-1, is not unexpected. W
is an amino acid frequently encountered in membrane active
peptides and has been shown to influence the localization of
these peptides into membrane interfaces (4, 5, 28, 32). Hence,
the effect of replacing the amino terminal F of TGN-1 by W
was evaluated. Replacing the N-terminal F by W generated
TGN-1W. In TGN-1WK in addition to this F-to-W change, T3
is replaced by K. TGN-1W was marginally more active than
TGN-1. Replacement of the polar amino acid T3 by cationic K
in TGN-1W further increased its activity. In TGN-1L (lin) the
two cysteine residues of TGN-1 are replaced by Ls, resulting in
a linear analog. TGN-1U (lin) is another linear analog of
TGN-1 with two alpha amino isobutyric acid residues in place
of cysteines. TGN-1LK (lin) is an analog of TGN-1 with Ks
replacing T3 and R. In contrast to the cyclic analogs, the linear
analogs showed considerable decrease in their antibacterial
activities; the most-active linear analog was TGN-1LK (lin).
TGN-1 adopts a -turn structure, and linearization could pre-
vent the formation of a turn structure. Thus, the -turn struc-
ture stabilized by the disulfide bridge appears to be essential
for the activity of TGN-1. The residual activity of the linear
analogs may stem from a fraction of molecules which could
populate a turn structure. Increasing the cationicity of the
linear analog [TGN-1 LK (lin)] appears to offset the need for
the disulfide bridge. The in vitro efficacies of TGN-1 and its
analogs in killing some clinical bacterial isolates were also
investigated. The microorganisms tested and the LCs of the
peptides against these strains are shown in Table 1. The mi-
crobes included highly virulent enteropathogenic strains of E.
coli and methicillin-resistant S. aureus. It is evident that the
majority of strains are susceptible to TGN-1 and its two ana-
logs. TGN-1W and TGN-1WK are generally more potent than
TGN-1. Strains of Proteus and Pseudomonas spp. were suscep-
TABLE 1. Sequences and activities of TGN-1 and its analogs
Peptide Sequencea
LC (g/ml) of peptide ford:
E. coli
W160-37
S. aureus
ATCC
8530
Rabbit
entero-
pathogenic
E. coli
Human
entero-
pathogenic
E. coli
Vibrio
cholerae
Pseudo-
monas
Klebsiella
pneumonia
Shigella
flexneri
Proteus
mirabilis MRSA
b
Salmonella
enterica
serovar
Typhi H
TGN-1 FCTMIPIPRCY-CONH2 10 10 35 25 120 150 50 70 150 50 45
TGN-1-OH FCTMIPIPRCY-COOH 200 200 NDc ND ND ND ND ND ND ND ND
TGN-1W WCTMIPIPRCY-CONH2 6 6 15 10 30 100 40 30 100 40 30
TGN-1WK WCKMIPIPRCY-CONH2 4 4 15 10 30 30 20 15 80 15 20
TGN-1L (lin) WLTMIPIPRLY-CONH2 160 200 ND ND ND ND ND ND ND ND ND
TGN-1LK (lin) WLKLIPIPKLY-CONH2 25 25 ND ND ND ND ND ND ND ND ND
TGN-1U (lin) WUTMIPIPRUY-CONH2 120 120 ND ND ND ND ND ND ND ND ND
a All cysteine containing peptides were linked by a disulfide bridge.
b MRSA, methicillin-resistant S. aureus.
c ND, not determined.
d Strains mentioned in the last nine columns are clinical strains obtained from Postgraduate Institute of Basic Medical Sciences, Chennai, India.
2280 NOTES ANTIMICROB. AGENTS CHEMOTHER.
tible to relatively high concentrations of the peptides. It has
been shown recently that a modified lipopolysaccharide struc-
ture in Proteus mirabilis strains make them less susceptible to
antimicrobial peptides (19). The peptides did not exhibit he-
molytic activity up to a concentration of 50 g/ml (highest
concentration tested).
The kinetics of killing of E. coli and S. aureus by TGN-1 and
its analogs were investigated. The results of the disulfide
bridge-containing analogs are shown in Fig. 1. About 99% of
cells were killed by TGN-1 after incubation of the cells with 6-
g/ml concentration of the peptide for 2 h (Fig. 1A and D).
More-rapid killing was evident in the cases of TGN-1W and
TGN-1WK. Complete killing was evident with these peptides
at a concentration of 6 g/ml after 60 and 40 min of incu-
bation, respectively, in the case of E. coli (Fig. 1A). The cor-
responding incubation periods are 20 and 10 min in the case
of S. aureus (Fig. 1D). At higher concentrations of these pep-
tides, cells were killed in much shorter periods of incubation
(Fig. 1B, C, E, and F). Thus, the analogs TGN-1W and TGN-
1WK are more effective in killing bacteria than their parent
peptide TGN-1. The kinetics of killing of E. coli and S. aureus
cells by the linear analog TGN-1LK (lin) were also investi-
gated. With this peptide at a concentration of 25 g/ml, E. coli
cells were killed after an incubation of 40 min and S. aureus
cells were killed in 120 min (results not shown).
Tigerinins have earlier been shown to permeabilize bacterial
membranes to N-phenyl-1-N-napthylamine and o-nitrophenyl-
-D-galactopyranoside (27). It can be reasonably assumed that
the activities of the analogs of TGN-1 used in this study also
are mediated by membrane permeabilization. The morpholo-
gies of E. coli cells treated with TGN-1 and analogs were
examined by electron microscopy. It was necessary to use high
concentrations of bacteria (109 CFU/ml) to prepare samples
for transmission electron microscopy compared to 106
CFU/ml for determining the LCs. To ensure that the ratios of
peptide to bacteria were similar in LC measurements and in
preparing samples for transmission electron microscopy, 108
cells in 100 l were treated with 70 g of the peptides. Nega-
tive staining revealed that a longer duration of incubation (1
h) of E. coli cells with lytic concentrations of TGN-1 caused
FIG. 1. Kinetics of killing of bacteria by TGN-1 and its analogs. (A, B, and C) E. coli; (D, E, and F) S. aureus. Cells in the mid-logarithmic phase
of growth (105 CFU) were incubated with different concentrations of tigerinins (6 g/ml [A and D], 8 g/ml [B and E], 10 g/ml [C and F]), and
aliquots were drawn out at different intervals after incubation and were placed on plated with nutrient broth. The number of colonies developed
was determined after incubating the plates for 18 h at 37°C. Cells incubated in the absence of any peptide served as controls. Symbols: circle,
TGN-1; square, TGN-1W; triangle, TGN-1WK.
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total lysis of cells, and very few cells were visible. Hence, the
effect of incubation of cells for short durations was examined
after fixing and sectioning. At 5 min of incubation (Fig. 2B)
with LCs of TGN-1, thickening of the outer surface and blebs
were discernible. The cytoplasmic membrane showed invagi-
nation, and the appearance of vacuoles in the cytoplasm was
evident. After 15 min of incubation (Fig. 2C), membrane dis-
continuity and leakage of entire cytoplasmic contents were
observed in many cells. The effect of TGN-1WK was very
similar to that of TGN-1 (Fig. 2D), indicating that both the
peptides exert their activities by similar mechanisms. These
studies demonstrated that treatment of E. coli cells with
TGN-1 and TGN-1WK leads to leakage of cytoplasmic con-
tents, and the membrane permeabilization earlier observed
may mediate this leakage. However, activation of autolytic
mechanisms by the peptide cannot be ruled out.
Thus, tigerinins are short peptides with a novel flexible struc-
tural motif, and the studies reported here demonstrate that it
is possible to improve the activity of short nonhelical peptides
by rational design of analogs and that these analogs hold prom-
ise as novel lead molecules for designing therapeutic mole-
cules.
K.P.S. thanks the Council for Scientific and Industrial Research,
New Delhi, India, for an award of Research Associateship.
We acknowledge the contribution of Usha Ananda Rao, Postgrad-
uate Institute of Basic Medical Sciences, Chennai, India, in the col-
lection of various clinical isolates used in the study and the experimen-
tal set. We thank M. Vairamani, Indian Institute of Chemical
Technology, Hyderabad, India, for mass spectral analysis.
REFERENCES
1. Andreu, D., and L. Rivas. 1998. Animal antimicrobial peptides: an overview.
Biopolymers 47:415–433.
2. Atherton, E., and R. C. Sheppard. 1989. Solid phase peptide synthesis: a
practical approach. IRL, Oxford, United Kingdom.
3. Bevins, C. L., and M. Zasloff. 1990. Peptides from frog skin. Annu. Rev.
Biochem. 59:395–410.
4. Blondelle, S. E., and R. A. Houghten. 1991. Hemolytic and antimicrobial
activities of the twenty-four individual omission analogues of melittin. Bio-
chemistry 30:4671–4678.
5. Blondelle, S. E., and R. A. Houghten. 1991. Probing the relationships be-
tween the structure and hemolytic activity of melittin with a complete set of
leucine substitution analogs. Peptide Res. 4:12–18.
6. Boman, H. C. 1995. Peptide antibiotics and their role in innate immunity.
Annu. Rev. Immunol. 13:61–92.
7. Broekaert, W. E. F., B. P. A. Cammue, M. F. C. De Bolle, K. Thevissen, G. W.
De Samblanx, and R. W. Osborn. 1997. Antimicrobial peptides from plants.
Crit. Rev. Plant Sci. 16:297–323.
8. Bulet, P., C. Hetru, J. L. Dimarcq, and D. Hoffmann. 1999. Antimicrobial
peptides in insects; structure and function. Dev. Comp. Immunol. 23:329–
344.
9. Chen, J., T. J. Falla, H. Liu, M. A. Hurst, C. A. Fujii, D. A. Mosca, J. R.
Embree, D. J. Loury, P. A. Radel, C. C. Chang, L. Gu, and J. C. Fiddes. 2000.
Development of protegrins for the treatment and prevention of oral mucosi-
tis: structure activity relationships of synthetic protegrin analogues. Biopoly-
mers 55:88–98.
10. Chopra, I., J. Hodgson, B. Metcalf, and G. Poste. 1997. The search for
antimicrobial agents effective against bacteria resistant to multiple antibiot-
ics. Antimicrob. Agents Chemother. 41:497–503.
11. Fehlbaum, P., P. Bulet, S. Chernysh, J. P. Briand, J. P. Roussel, L. Letellier,
C. Hetru, and J. Hoffmann. 1996. Structure activity analysis of thanatin, a
21-residue inducible insect defense peptide with sequence homology to frog
skin antimicrobial peptides. Proc. Natl. Acad. Sci. USA 93:1221–1225.
12. Ganz, T. 1999. Defensins and host defense. Science 286:420–421.
13. Hancock, R. E. 1997. Peptide antibiotics. Lancet 349:418–422.
14. Hancock, R. E., and G. Diamond. 2000. The role of cationic antimicrobial
peptides in innate host defences. Trends Microbiol. 8:402–410.
15. Huang, H. W. 2000. Action of antimicrobial peptides: two-state model. Bio-
chemistry 39:8347–8352.
16. Kwon, M. Y., S. Y. Hong., and K. H. Lee. 1998. Structure-activity analysis of
brevinin 1E amide, an antimicrobial peptide from Rana esulenta. Biochim.
Biophys. Acta 1387:239–248.
17. Lehrer, R. I., K. A. Barton, S. S. L. Harwig, T. Ganz, and M. E. Selsted. 1989.
Interaction of human defensins with Escherichia coli. Mechanism of bacte-
ricidal activity. J. Clin. Investig. 137:167–173.
18. Maloy, W. L., and U. P. Kari. 1995. Structure-activity studies on magainins
and other host defense peptides. Biopolymers 37:105–122.
19. McCoy, A. J., H. Liu., T. J. Falla, and J. S. Gunn. 2001. Identification of
Proteus mirabilis mutants with increased sensitivity to antimicrobial peptides.
Antimicrob. Agents Chemother. 45:2030–2037.
20. Neu, H. C. 1992. The crisis in antibiotic resistance. Science 257:1064–1073.
21. Nicolos, P., and A. Mor. 1995. Peptides as weapons against microorganisms
in the chemical defense system of vertebrates. Annu. Rev. Microbiol. 49:
277–304.
22. Oren, Z., and Shai. 1999. Mode of action of amphipathic -helical antimi-
crobial peptides. Biopolymers. 47:451–463.
FIG. 2. Transmission electron micrographs of E. coli cells before treatment (A), 5 min after incubation with TGN-1 (B), 15 min after incubation
with TGN-1 (C), and 15 min after incubation with TGN-1WK (D). Details are given in the materials and methods section. Arrows point out the
membrane discontinuity. Magnification, 25,000.
2282 NOTES ANTIMICROB. AGENTS CHEMOTHER.
23. Ponti, D., G. Hignoma, L. Hangoni, D. de Biase, H. Simmaco, and D. Barra.
1999. Expression and activity of cyclic and linear analogues of esculentin-1, an
antimicrobial peptide from amphibian skin. Eur. J. Biochem. 263:921–927.
24. Rao, A. G. 1999. Conformation and antimicrobial activity of linear deriva-
tives of tachyplesin lacking disulfide bonds. Arch. Biochem. Biophys. 361:
127–134.
25. Romeo, D., B. Skerlavaj., M. Bolognesi, and R. Gennaro. 1998. Structure and
bactericidal activity of an antibiotic dodecapeptide purified from bovine
neutrophils. J. Biol. Chem. 263:9573–9575.
26. Saberwal, G., and R. Nagaraj. 1994. Cell lytic and antibacterial peptides that
act by perturbing the barrier function of membranes: facets of their confor-
mational features, structure-function correlations and membrane-perturbing
abilities. Biochim. Biophys. Acta 1197:109–131.
27. Sai, K. P., M. V. Jagannadham, M. Vairamani, N. P. Raju, A. S. Devi, R.
Nagaraj, and N. Sitaram. 2001. Tigerinins: novel antimicrobial peptides
from the Indian frog Rana tigerina. J. Biol. Chem. 276:2701–2707.
28. Schiffer, M., C. H. Chang, and F. J. Stevens. 1992. The functions of trypto-
phan residues in membrane proteins. Protein. Eng. 5:213–214.
29. Simmaco, M., G. Mignogna, and D. Barra. 1999. Antimicrobial peptides
from amphibian skin: what do they tell us? Biopolymers 47:435–450.
30. Sitaram, N., and R. Nagaraj. 1990. A synthetic 13-residue peptide corre-
sponding to the hydrophobic region of bovine seminalplasmin has antibac-
terial activity and also causes lysis of red blood cells. J. Biol. Chem. 265:
10438–10442.
31. Sitaram, N., and R. Nagaraj. 1999. Interaction of antimicrobial peptides with
biological and model membranes: structural and charge requirements for
activity. Biochim. Biophys. Acta 1462:29–54.
32. Subbalakshmi, C., V. Krishnakumari, R. Nagaraj, and N. Sitaram. 1996.
Requirements for antibacterial and hemolytic activities in the bovine neu-
trophil derived 13-residue peptide indolicidin. FEBS Lett. 395:48–52.
33. Subbalakshmi, C., and N. Sitaram. 1998. Mechanism of antimicrobial action
of indolicidin. FEMS Microbiol. Lett. 160:91–96.
34. Tam, J., P., C. R. Wu, W. Liu, and J. W. Zhang. 1991. Disulfide bond
formation in peptides by dimethyl sulfoxide. Scope and applications. J. Am.
Chem. Soc. 113:6657–6662.
35. Tossi, A., L. Sandri, and A. Giangaspero. 2000. Amphipathic, alpha-helical
antimicrobial peptides. Biopolymers 55:4–30.
36. Walsh, C. 2000. Molecular mechanisms that confer antibacterial drug resis-
tance. Nature 406:775–787.
37. Wu, M., and R. E. Hancock. 1999. Interaction of the cyclic antimicrobial
peptide bactenecin with the outer and cytoplasmic membrane. J. Biol. Chem.
274:29–35.
38. Wu, M., and R. E. Hancock. 1999. Improved derivatives of bactenecin, a
cyclic dodecameric cationic peptide. Antimicrob. Agents Chemother. 43:
1274–1276.
39. Zhang, L., A. Rozek, and R. E. Hancock. 2001. Interaction of cationic anti-
microbial peptides with model membranes. J. Biol. Chem. 276:35174–35722.
VOL. 46, 2002 NOTES 2283
